AngioDynamics to Participate in Upcoming Investor Conferences
Get Alerts ANGO Hot Sheet
Join SI Premium – FREE
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is scheduled to participate in the following upcoming investor conferences:
9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Date: August 12, 2024
Canaccord Genuity 44th Annual Growth Conference
Presentation: August 13, 2024 at 10:00am
A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.angiodynamics.com.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729308520/en/
Investors:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408
Source: AngioDynamics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hotel and Gaming Trades Council Members Begin Picketing at Two Times Square Hotels
- RENTAL INCOME UP +4% IN H1 2026 AND TARGET FOR THE YEAR REVISED UPWARDS TO €221M (VS. €220M PREVIOUSLY)
- Nexity: Total number of voting rights and shares composing the share capital as of 30 June 2026
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Needham & Company, Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share